Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
HUTCHMED (China) ( (HK:0013) ) has issued an update.
HUTCHMED announced the approval of its drug combination ORPATHYS® and TAGRISSO® by China’s National Medical Products Administration for treating lung cancer patients with MET amplification after progression on first-line EGFR inhibitor therapy. This approval, based on the SACHI Phase III trial, marks a significant advancement in lung cancer treatment, offering a chemotherapy-free, all-oral option that reduces disease progression risk by 66%. The approval also triggers a milestone payment from AstraZeneca, underscoring the strategic collaboration between the two companies to address resistance in NSCLC treatment and expand this innovative therapy’s reach in China and potentially globally.
More about HUTCHMED (China)
HUTCHMED (China) Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company operates primarily in China and collaborates with global pharmaceutical companies like AstraZeneca to enhance its market reach.
Find detailed analytics on 0013 stock on TipRanks’ Stock Analysis page.